Bone marrow-derived mesenchymal stem cells drive lymphangiogenesis

Autor: Agnès Noël, Ludovic Maertens, Benoît Detry, Bénédicte Lenoir, Julie Lecomte, Jenny Paupert, Didier Cataldo, Silvia Blacher, Charlotte Erpicum, Oriane Carnet, Christel Pequeux
Rok vydání: 2014
Předmět:
Vascular Endothelial Growth Factor A
Cell signaling
Angiogenesis
lcsh:Medicine
Signal transduction
chemistry.chemical_compound
Mice
Cell Movement
Animal Cells
Medicine and Health Sciences
Lymphangiogenesis
Phosphorylation
lcsh:Science
Multidisciplinary
Stem Cells
VEGF signaling
Vascular endothelial growth factor
Endothelial stem cell
Vascular endothelial growth factor A
Lymphatic Endothelium
Cell Motility
Lymphatic system
Cell Processes
Female
Anatomy
Cellular Types
Research Article
medicine.medical_specialty
Cell biology
MAP Kinase Signaling System
government.form_of_government
Biology
Lymphatic System
Paracrine signalling
Internal medicine
medicine
Animals
Cell Proliferation
Biology and life sciences
lcsh:R
Endothelial Cells
Mesenchymal Stem Cells
Mice
Inbred C57BL

Endocrinology
Receptors
Vascular Endothelial Growth Factor

chemistry
Culture Media
Conditioned

Cancer research
government
lcsh:Q
Zdroj: PLoS ONE
PLoS ONE, Vol 9, Iss 9, p e106976 (2014)
ISSN: 1932-6203
Popis: It is now well accepted that multipotent Bone-Marrow Mesenchymal Stem Cells (BM-MSC) contribute to cancer progression through several mechanisms including angiogenesis. However, their involvement during the lymphangiogenic process is poorly described. Using BM-MSC isolated from mice of two different backgrounds, we demonstrate a paracrine lymphangiogenic action of BM-MSC both in vivo and in vitro. Co-injection of BM-MSC and tumor cells in mice increased the in vivo tumor growth and intratumoral lymphatic vessel density. In addition, BM-MSC or their conditioned medium stimulated the recruitment of lymphatic vessels in vivo in an ear sponge assay, and ex vivo in the lymphatic ring assay (LRA). In vitro, MSC conditioned medium also increased the proliferation rate and the migration of both primary lymphatic endothelial cells (LEC) and an immortalized lymphatic endothelial cell line. Mechanistically, these pro-lymphangiogenic effects relied on the secretion of Vascular Endothelial Growth Factor (VEGF)-A by BM-MSC that activates VEGF Receptor (VEGFR)-2 pathway on LEC. Indeed, the trapping of VEGF-A in MSC conditioned medium by soluble VEGF Receptors (sVEGFR)-1, -2 or the inhibition of VEGFR-2 activity by a specific inhibitor (ZM 323881) both decreased LEC proliferation, migration and the phosphorylation of their main downstream target ERK1/2. This study provides direct unprecedented evidence for a paracrine lymphangiogenic action of BM-MSC via the production of VEGF-A which acts on LEC VEGFR-2.
Databáze: OpenAIRE